Corona Remedies Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
5,686
- Stock Symbol
-
CORONA
- Investments
-
5
- Share Price
-
$24.78
- (As of Friday Closing)
Corona Remedies General Information
Description
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
Contact Information
Website
www.coronaremedies.comCorporate Office
- C, Mondeal Business Park
- Near Gurudwara. S.G. Highway, Thaltej
- Ahmedabad, Gujarat 380059
- India
Corporate Office
- C, Mondeal Business Park
- Near Gurudwara. S.G. Highway, Thaltej
- Ahmedabad, Gujarat 380059
- India
Corona Remedies Stock Performance
As of 13-Nov-2026, Corona Remedies’s stock price is $24.78. Its current market cap is $1.52B with 61.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $24.78 | $25.00 | $14.74 - $28.95 | $1.52B | 61.2M | 45.8K | $0.37 |
Corona Remedies Financials Summary
As of 30-Sep-2026, Corona Remedies has a trailing 12-month revenue of $168M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 1,349,933 | 1,003,791 | ||
| Revenue | 168,154 | 158,604 | 141,385 | 122,446 |
| EBITDA | 35,331 | 31,212 | 28,303 | 18,553 |
| Net Income | 22,328 | 20,950 | 17,672 | 10,932 |
| Total Assets | 129,800 | 127,727 | 108,706 | 99,597 |
| Total Debt | 11,989 | 17,472 | 10,082 | 19,061 |
Corona Remedies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Corona Remedies Comparisons
Industry
Financing
Details
Corona Remedies Competitors (45)
One of Corona Remedies’s 45 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Cipla | Corporation | Mumbai, India | ||||
| GSK | Corporation | London, United Kingdom |
Corona Remedies Patents
Corona Remedies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-2704143-B1 | Care bed on wheels. | Inactive | 21-Apr-1993 | ||
| FR-2704143-A1 | Treatment bed with castors | Active | 21-Apr-1993 |
Corona Remedies Signals
Corona Remedies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Corona Remedies Investments (5)
Corona Remedies’s most recent deal was a Corporate Asset Purchase with Dr. Reddy's (Wokadine Brand) for . The deal was made on 30-Mar-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dr. Reddy's (Wokadine Brand) | 30-Mar-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Bayer (Seven Pharmaceutical Brands in India) | 16-Jul-2025 | Buyout/LBO | Buildings and Property | ||
| Sanofi India (Myoril Brand) | 28-Jun-2023 | Buyout/LBO | Buildings and Property | ||
| Abbott India (Obimet and Thyrocab) | 02-Apr-2018 | Buyout/LBO | Buildings and Property | ||
| GlaxoSmithKline (Dilo-BM, Dilo-DX, Stelbid and Vitneurin) | 07-Mar-2017 | Buyout/LBO | Buildings and Property |
Corona Remedies ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Corona Remedies FAQs
-
When was Corona Remedies founded?
Corona Remedies was founded in 2004.
-
Where is Corona Remedies headquartered?
Corona Remedies is headquartered in Ahmedabad, India.
-
What is the size of Corona Remedies?
Corona Remedies has 5,686 total employees.
-
What industry is Corona Remedies in?
Corona Remedies’s primary industry is Pharmaceuticals.
-
Is Corona Remedies a private or public company?
Corona Remedies is a Public company.
-
What is Corona Remedies’s stock symbol?
The ticker symbol for Corona Remedies is CORONA.
-
What is the current stock price of Corona Remedies?
As of 13-Nov-2026 the stock price of Corona Remedies is $24.78.
-
What is the current market cap of Corona Remedies?
The current market capitalization of Corona Remedies is $1.52B.
-
What is Corona Remedies’s current revenue?
The trailing twelve month revenue for Corona Remedies is $168M.
-
Who are Corona Remedies’s competitors?
Biocon, Torrent Pharmaceuticals, Novartis, Cipla, and GSK are some of the 45 competitors of Corona Remedies.
-
What is Corona Remedies’s annual earnings per share (EPS)?
Corona Remedies’s EPS for 12 months was $0.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process